Neutralizing Antibodies against SARS-CoV-2 Beta and Omicron Variants Inhibition Comparison after BNT162b2 mRNA Booster Doses with a New PETIA sVNT Assay
Background: Monitoring antibody response following SARS-CoV-2 vaccination is strategic, and neutralizing antibodies represent the gold standard. The neutralizing response to Beta and Omicron VOCs was evaluated versus the gold standard by a new commercial automated assay. Methods: Serum samples from...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/5/889 |
| _version_ | 1797615520041664512 |
|---|---|
| author | Marta Fogolari Bruno Daniele Leoni Marina De Cesaris Rita Italiano Flavio Davini Ginevra Azzurra Miccoli Daniele Donati Luigi Clerico Andrea Stanziale Giovanni Savini Nicola Petrosillo Massimo Ciccozzi Lorenzo Sommella Elisabetta Riva Paolo Fazii Silvia Angeletti |
| author_facet | Marta Fogolari Bruno Daniele Leoni Marina De Cesaris Rita Italiano Flavio Davini Ginevra Azzurra Miccoli Daniele Donati Luigi Clerico Andrea Stanziale Giovanni Savini Nicola Petrosillo Massimo Ciccozzi Lorenzo Sommella Elisabetta Riva Paolo Fazii Silvia Angeletti |
| author_sort | Marta Fogolari |
| collection | DOAJ |
| description | Background: Monitoring antibody response following SARS-CoV-2 vaccination is strategic, and neutralizing antibodies represent the gold standard. The neutralizing response to Beta and Omicron VOCs was evaluated versus the gold standard by a new commercial automated assay. Methods: Serum samples from 100 healthcare workers from the Fondazione Policlinico Universitario Campus Biomedico and the Pescara Hospital were collected. IgG levels were determined by chemiluminescent immunoassay (Abbott Laboratories, Wiesbaden, Germany) and serum neutralization assay as the gold standard. Moreover, a new commercial immunoassay, the PETIA test Nab (SGM, Rome, Italy), was used for neutralization evaluation. Statistical analysis was performed with R software, version 3.6.0. Results: Anti-SARS-CoV-2 IgG titers decayed during the first ninety days after the vaccine second dose. The following booster dose significantly (<i>p</i> < 0.001) increased IgG levels. A correlation between IgG expression and neutralizing activity modulation was found with a significant increase after the second and the third booster dose (<i>p</i> < 0.05. Compared to the Beta variant of the virus, the Omicron VOC was associated with a significantly larger quantity of IgG antibodies needed to achieve the same degree of neutralization. The best Nab test cutoff for high neutralization titer (≥1:80) was set for both Beta and Omicron variants. Conclusion: This study correlates vaccine-induced IgG expression and neutralizing activity using a new PETIA assay, suggesting its usefulness for SARS-CoV2 infection management. |
| first_indexed | 2024-03-11T07:27:41Z |
| format | Article |
| id | doaj.art-77653563d402498dbedf899c1059b9a4 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-11T07:27:41Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-77653563d402498dbedf899c1059b9a42023-11-17T07:29:34ZengMDPI AGDiagnostics2075-44182023-02-0113588910.3390/diagnostics13050889Neutralizing Antibodies against SARS-CoV-2 Beta and Omicron Variants Inhibition Comparison after BNT162b2 mRNA Booster Doses with a New PETIA sVNT AssayMarta Fogolari0Bruno Daniele Leoni1Marina De Cesaris2Rita Italiano3Flavio Davini4Ginevra Azzurra Miccoli5Daniele Donati6Luigi Clerico7Andrea Stanziale8Giovanni Savini9Nicola Petrosillo10Massimo Ciccozzi11Lorenzo Sommella12Elisabetta Riva13Paolo Fazii14Silvia Angeletti15Clinical Laboratory Unit, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, ItalyAbbott, Core Diagnostics, 00144 Rome, ItalyClinical Laboratory Unit, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, ItalyAbbott, Core Diagnostics, 00144 Rome, ItalyClinical Laboratory Unit, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, ItalyInfection Prevention and Control Service, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, ItalyInfection Prevention and Control Service, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, ItalyClinical Microbiology and Virology, Spirito Santo Hospital, 65122 Pescara, ItalyClinical Microbiology and Virology, Spirito Santo Hospital, 65122 Pescara, ItalyIstituto Zooprofilattico Sperimentale dell’Abruzzo e del Molise ‘G Caporale’, 64100 Teramo, ItalyInfection Prevention and Control Service, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, ItalyUnit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, 00128 Rome, ItalyHealth Management, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, ItalyClinical Laboratory Unit, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, ItalyClinical Microbiology and Virology, Spirito Santo Hospital, 65122 Pescara, ItalyClinical Laboratory Unit, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, ItalyBackground: Monitoring antibody response following SARS-CoV-2 vaccination is strategic, and neutralizing antibodies represent the gold standard. The neutralizing response to Beta and Omicron VOCs was evaluated versus the gold standard by a new commercial automated assay. Methods: Serum samples from 100 healthcare workers from the Fondazione Policlinico Universitario Campus Biomedico and the Pescara Hospital were collected. IgG levels were determined by chemiluminescent immunoassay (Abbott Laboratories, Wiesbaden, Germany) and serum neutralization assay as the gold standard. Moreover, a new commercial immunoassay, the PETIA test Nab (SGM, Rome, Italy), was used for neutralization evaluation. Statistical analysis was performed with R software, version 3.6.0. Results: Anti-SARS-CoV-2 IgG titers decayed during the first ninety days after the vaccine second dose. The following booster dose significantly (<i>p</i> < 0.001) increased IgG levels. A correlation between IgG expression and neutralizing activity modulation was found with a significant increase after the second and the third booster dose (<i>p</i> < 0.05. Compared to the Beta variant of the virus, the Omicron VOC was associated with a significantly larger quantity of IgG antibodies needed to achieve the same degree of neutralization. The best Nab test cutoff for high neutralization titer (≥1:80) was set for both Beta and Omicron variants. Conclusion: This study correlates vaccine-induced IgG expression and neutralizing activity using a new PETIA assay, suggesting its usefulness for SARS-CoV2 infection management.https://www.mdpi.com/2075-4418/13/5/889SARS-CoV-2VOCsserum antibodiesvaccineneutralization assayPETIA assay |
| spellingShingle | Marta Fogolari Bruno Daniele Leoni Marina De Cesaris Rita Italiano Flavio Davini Ginevra Azzurra Miccoli Daniele Donati Luigi Clerico Andrea Stanziale Giovanni Savini Nicola Petrosillo Massimo Ciccozzi Lorenzo Sommella Elisabetta Riva Paolo Fazii Silvia Angeletti Neutralizing Antibodies against SARS-CoV-2 Beta and Omicron Variants Inhibition Comparison after BNT162b2 mRNA Booster Doses with a New PETIA sVNT Assay Diagnostics SARS-CoV-2 VOCs serum antibodies vaccine neutralization assay PETIA assay |
| title | Neutralizing Antibodies against SARS-CoV-2 Beta and Omicron Variants Inhibition Comparison after BNT162b2 mRNA Booster Doses with a New PETIA sVNT Assay |
| title_full | Neutralizing Antibodies against SARS-CoV-2 Beta and Omicron Variants Inhibition Comparison after BNT162b2 mRNA Booster Doses with a New PETIA sVNT Assay |
| title_fullStr | Neutralizing Antibodies against SARS-CoV-2 Beta and Omicron Variants Inhibition Comparison after BNT162b2 mRNA Booster Doses with a New PETIA sVNT Assay |
| title_full_unstemmed | Neutralizing Antibodies against SARS-CoV-2 Beta and Omicron Variants Inhibition Comparison after BNT162b2 mRNA Booster Doses with a New PETIA sVNT Assay |
| title_short | Neutralizing Antibodies against SARS-CoV-2 Beta and Omicron Variants Inhibition Comparison after BNT162b2 mRNA Booster Doses with a New PETIA sVNT Assay |
| title_sort | neutralizing antibodies against sars cov 2 beta and omicron variants inhibition comparison after bnt162b2 mrna booster doses with a new petia svnt assay |
| topic | SARS-CoV-2 VOCs serum antibodies vaccine neutralization assay PETIA assay |
| url | https://www.mdpi.com/2075-4418/13/5/889 |
| work_keys_str_mv | AT martafogolari neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay AT brunodanieleleoni neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay AT marinadecesaris neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay AT ritaitaliano neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay AT flaviodavini neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay AT ginevraazzurramiccoli neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay AT danieledonati neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay AT luigiclerico neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay AT andreastanziale neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay AT giovannisavini neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay AT nicolapetrosillo neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay AT massimociccozzi neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay AT lorenzosommella neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay AT elisabettariva neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay AT paolofazii neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay AT silviaangeletti neutralizingantibodiesagainstsarscov2betaandomicronvariantsinhibitioncomparisonafterbnt162b2mrnaboosterdoseswithanewpetiasvntassay |